Clinical Study Reveals Orthogen LLC Nanotechnology-Based Product, NanoGen, Safe for Patients with Chronic Periodontitis
After years of research and development, Orthogen LLC has been issued a patent for their commercialized and novel dental bone graft material, NanoGen. The product became the first nanotechnology-based dental bone graft allowed for marketing by the FDA. Over last 2 years, a clinical study was conducted to test the use of NanoGen in infrabony defects in patients with chronic periodontitis. Orthogen LLC is proud to announce that the study concluded, their development—NanoGen—was considered highly valuable in the treatment of...
View full press release